JP7849353B2 - オフターゲット活性が低減された修飾ｓｉＲＮＡ - Google Patents

オフターゲット活性が低減された修飾ｓｉＲＮＡ

Info

Publication number
JP7849353B2
JP7849353B2 JP2023507494A JP2023507494A JP7849353B2 JP 7849353 B2 JP7849353 B2 JP 7849353B2 JP 2023507494 A JP2023507494 A JP 2023507494A JP 2023507494 A JP2023507494 A JP 2023507494A JP 7849353 B2 JP7849353 B2 JP 7849353B2
Authority
JP
Japan
Prior art keywords
group
sirna
modified
nucleotide
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023507494A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536320A5 (enExample
JP2023536320A (ja
Inventor
金宇 黄
敏 羅
科 尹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tuojie Biotech Shanghai Co Ltd
Original Assignee
Tuojie Biotech Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tuojie Biotech Shanghai Co Ltd filed Critical Tuojie Biotech Shanghai Co Ltd
Publication of JP2023536320A publication Critical patent/JP2023536320A/ja
Publication of JP2023536320A5 publication Critical patent/JP2023536320A5/ja
Application granted granted Critical
Publication of JP7849353B2 publication Critical patent/JP7849353B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/313—Phosphorodithioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/319—Chemical structure of the backbone linked by 2'-5' linkages, i.e. having a free 3'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3235—Chemical structure of the sugar modified ring structure having the O of the ribose replaced by another atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/332—Abasic residue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
JP2023507494A 2020-08-04 2021-08-04 オフターゲット活性が低減された修飾ｓｉＲＮＡ Active JP7849353B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202010772542.6 2020-08-04
CN202010772542 2020-08-04
CN202110244977.8 2021-03-05
CN202110244977 2021-03-05
CN202110361502.7 2021-04-02
CN202110361502 2021-04-02
PCT/CN2021/110509 WO2022028462A1 (zh) 2020-08-04 2021-08-04 脱靶活性降低的修饰sirna

Publications (3)

Publication Number Publication Date
JP2023536320A JP2023536320A (ja) 2023-08-24
JP2023536320A5 JP2023536320A5 (enExample) 2024-07-30
JP7849353B2 true JP7849353B2 (ja) 2026-04-21

Family

ID=80120017

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507494A Active JP7849353B2 (ja) 2020-08-04 2021-08-04 オフターゲット活性が低減された修飾ｓｉＲＮＡ

Country Status (10)

Country Link
US (1) US20230287418A1 (enExample)
EP (1) EP4194553A4 (enExample)
JP (1) JP7849353B2 (enExample)
KR (1) KR20230043195A (enExample)
CN (1) CN115955973A (enExample)
BR (1) BR112023002080A2 (enExample)
CA (1) CA3190097A1 (enExample)
TW (1) TW202214858A (enExample)
WO (1) WO2022028462A1 (enExample)
ZA (1) ZA202303275B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
TW202302851A (zh) * 2021-04-02 2023-01-16 大陸商上海拓界生物醫藥科技有限公司 Ｂ型肝炎病毒ｓｉＲＮＡ和ｓｉＲＮＡ綴合物
CA3216332A1 (en) * 2021-04-22 2022-10-27 Tuojie Biotech (Shanghai) Co., Ltd. Sirna targeting 17b-hydroxysteroid dehydrogenase type 13 and sirna conjugate
CN118339294A (zh) * 2021-12-16 2024-07-12 上海拓界生物医药科技有限公司 一种dsRNA、其制备方法及应用
TW202340469A (zh) * 2022-01-20 2023-10-16 大陸商上海拓界生物醫藥科技有限公司 一種ｄｓｒｎａ、其應用及製備方法
JP2025541262A (ja) * 2022-12-13 2025-12-18 上海拓界生物医薬科技有限公司 親油性モノマーを含むオリゴヌクレオチド及びその非肝臓送達における使用
WO2024175013A1 (zh) * 2023-02-21 2024-08-29 成都先导药物开发股份有限公司 核苷酸类似物及其制备方法和用途
WO2024179573A1 (zh) 2023-03-02 2024-09-06 上海拓界生物医药科技有限公司 靶向抑制素βE的siRNA、siRNA缀合物及其医药用途
EP4700125A2 (en) * 2023-04-21 2026-02-25 Suzhou Siran Biotechnology Co., Ltd. Oligomeric nucleic acid, and preparation method therefore and use thereof
CN120957994A (zh) 2023-04-27 2025-11-14 上海森辉医药有限公司 用于制备寡核苷酸类似物或其盐的中间体及其制备方法
CN121079106A (zh) 2023-05-31 2025-12-05 上海拓界生物医药科技有限公司 一种靶向LPA的dsRNA及其应用
TW202503060A (zh) 2023-06-13 2025-01-16 大陸商上海拓界生物醫藥科技有限公司 靶向ＭＭＰ７的ｓｉＲＮＡ、ｓｉＲＮＡ綴合物及其醫藥用途
WO2025007907A1 (zh) * 2023-07-04 2025-01-09 大睿生物 包含肽的寡核苷酸递送配体
AU2024315297A1 (en) 2023-08-01 2026-02-12 Tuojie Biotech (Shanghai) Co., Ltd. Dsrna targeting mapt and pharmaceutical use thereof
TW202509217A (zh) 2023-08-24 2025-03-01 大陸商上海拓界生物醫藥科技有限公司 靶向ＲＡＧＥ的ＲＮＡｉ劑及其醫藥用途
TW202526017A (zh) * 2023-09-14 2025-07-01 美商Ionis製藥公司 用於減少ａｐｏｃｉｉｉ表現的化合物及方法
AU2024351190A1 (en) * 2023-09-26 2026-03-26 Tuojie Biotech (Shanghai) Co., Ltd. Lipid-modified nucleic acid compound, and preparation method and use therefor
CN120209036A (zh) * 2023-12-26 2025-06-27 广东东阳光药业股份有限公司 一种新型的化合物及其用途
WO2026002138A1 (zh) * 2024-06-27 2026-01-02 成都新泽利医药科技有限公司 特定修饰的双链寡核苷酸及其组合物
CN119410644A (zh) * 2025-01-08 2025-02-11 北京安龙生物医药有限公司 修饰的双链寡核苷酸及其缀合物和组合物
CN119528986B (zh) * 2025-01-23 2025-09-16 北京悦康科创医药科技股份有限公司 一种核苷类似物及其在降低寡核苷酸药物脱靶活性中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019222479A1 (en) 2018-05-16 2019-11-21 Alnylam Pharmaceuticals, Inc. Modified rna agents with reduced off-target effect
JP2019535288A (ja) 2016-11-23 2019-12-12 アルニラム・ファーマシューティカルズ・インコーポレーテッド オフターゲット効果が低下した修飾ｒｎａ剤
JP2024515194A (ja) 2021-04-22 2024-04-05 上海拓界生物医薬科技有限公司 １７β－ヒドロキシステロイドデヒドロゲナーゼの１３型を標的とするｓｉＲＮＡ及びｓｉＲＮＡ複合体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4887500B2 (ja) * 2004-09-16 2012-02-29 国立大学法人岐阜大学 ヌクレオシド類似体またはその塩
CA2715289C (en) * 2008-02-11 2019-12-24 Rxi Pharmaceuticals Corporation Modified rnai polynucleotides and uses thereof
SG171879A1 (en) * 2008-12-03 2011-07-28 Marina Biotech Inc Usirna complexes
AU2013299717B2 (en) 2012-08-06 2018-06-28 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugated RNA agents and process for their preparation
JP2017535552A (ja) * 2014-11-17 2017-11-30 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． アポリポタンパク質Ｃ３（ＡＰＯＣ３）ｉＲＮＡ組成物およびその使用方法
BR112018008344A2 (pt) * 2015-12-13 2018-10-30 Nitto Denko Corp molécula de ácido nucleico, composição farmacêutica, vetor ou célula, método para prevenir, tratar ou melhorar uma doença, e, uso de uma composição
CN107400669A (zh) * 2016-08-18 2017-11-28 广州市锐博生物科技有限公司 用于抑制HIF1A靶基因mRNA表达的寡核酸分子及其成套组合物
CN111378657B (zh) * 2018-12-28 2024-03-15 苏州瑞博生物技术股份有限公司 抑制COL1A1基因表达的siRNA、含有该siRNA的药物组合物及其用途
CN111378655B (zh) * 2018-12-28 2024-03-19 苏州瑞博生物技术股份有限公司 抑制CTGF基因表达的siRNA、含有该siRNA的药物组合物及其用途
CN111378656B (zh) * 2018-12-28 2022-07-26 苏州瑞博生物技术股份有限公司 一种抑制埃博拉病毒的核酸、含有该核酸的药物组合物及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019535288A (ja) 2016-11-23 2019-12-12 アルニラム・ファーマシューティカルズ・インコーポレーテッド オフターゲット効果が低下した修飾ｒｎａ剤
WO2019222479A1 (en) 2018-05-16 2019-11-21 Alnylam Pharmaceuticals, Inc. Modified rna agents with reduced off-target effect
JP2024515194A (ja) 2021-04-22 2024-04-05 上海拓界生物医薬科技有限公司 １７β－ヒドロキシステロイドデヒドロゲナーゼの１３型を標的とするｓｉＲＮＡ及びｓｉＲＮＡ複合体

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ChemBioChem，2014年，Vol.15, No.17，p.2549-2555
FEBS Letters，2005年，Vol.579, No.14，p.3115-3118
J. Am. Chem. Soc.，2017年，Vol.139, No.25，p.8537-8546
Molecules，2015年，Vol.20, No.5，p.7602-7619
Org. Biomol. Chem.，2015年，Vol.13, No.8，p.2366-2374

Also Published As

Publication number Publication date
EP4194553A4 (en) 2024-11-13
CA3190097A1 (en) 2022-02-10
KR20230043195A (ko) 2023-03-30
BR112023002080A2 (pt) 2023-04-25
WO2022028462A1 (zh) 2022-02-10
CN115955973A (zh) 2023-04-11
TW202214858A (zh) 2022-04-16
EP4194553A1 (en) 2023-06-14
JP2023536320A (ja) 2023-08-24
US20230287418A1 (en) 2023-09-14
ZA202303275B (en) 2025-12-17

Similar Documents

Publication Publication Date Title
JP7849353B2 (ja) オフターゲット活性が低減された修飾ｓｉＲＮＡ
CN113474328B (zh) 用于脂质纳米颗粒递送活性剂的脂质
JP2024524330A (ja) 核酸リガンド及びその複合体、その調製方法と用途
JP2023179555A (ja) 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用
TW202122093A (zh) 化合物、藥物綴合物、試劑盒及其用途
WO2023208023A1 (zh) 氘代化学修饰和包含其的寡核苷酸
JP2024515194A (ja) １７β－ヒドロキシステロイドデヒドロゲナーゼの１３型を標的とするｓｉＲＮＡ及びｓｉＲＮＡ複合体
TW202340466A (zh) 一種ｄｓｒｎａ、其製備方法及應用
WO2020233651A1 (zh) 核酸、药物组合物与缀合物及制备方法和用途
JP2025500860A (ja) ｄｓＲＮＡ、その調製方法及び使用
TW202302851A (zh) Ｂ型肝炎病毒ｓｉＲＮＡ和ｓｉＲＮＡ綴合物
JP2026506685A (ja) プログラム細胞死リガンド１遺伝子の発現を抑制するためのｓｉＲＮＡ、そのコンジュゲート及び医薬組成物並びにその用途
TW202334424A (zh) 一種ｄｓｒｎａ、其製備方法及應用
JP2025504845A (ja) ｄｓＲＮＡ、その使用及び調製方法
JP2026513376A (ja) オリゴヌクレオチド及びその製造方法と応用
TW202339773A (zh) 一種ｄｓＲＮＡ、其應用及製備方法
RU2849194C1 (ru) МОДИФИЦИРОВАННАЯ миРНК С ПОНИЖЕННОЙ НЕЦЕЛЕВОЙ АКТИВНОСТЬЮ
CN119264203A (zh) 一类5’-端修饰的2’,5’-连接核苷酸及其在RNAi中的应用
CN120209036A (zh) 一种新型的化合物及其用途
EA052594B1 (ru) Конъюгат нуклеиновой кислоты и лиганда, способ его получения и его применения
CN121450643A (zh) 一种靶向AGT的双链siRNA、其缀合物及其用途

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240722

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251208

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260324

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260409

R150 Certificate of patent or registration of utility model

Ref document number: 7849353

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150